How ivacaftor changes inflammation and protein levels in the bloodstream of people with CF and the G551D mutation
Results of a clinical evaluation of the safety and efficacy of the therapeutic drug candidate Roscovitine in people with cystic fibrosis.
What do we already know and what do we need to study next when looking at markers of inflammation in sputum in CF trials?
